Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) Stock Ticker

NASDAQ: IMVT · Healthcare · Biotechnology
$33.30-2.06%
USD · as of 2026-09-28 · market cap $6.9B
Open IMVT in TickrDownload for iPhone

IMVT right now

22% of the float is sold short.
Options expect by Oct 6±10.9%
Options expect by Oct 29±22.6%
Priced in for Nov 9 earnings±26.5%
IV rank (30-day)48% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full IMVT picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on IMVT
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Immunovant, Inc.

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

IMVT stock facts

Ticker symbolIMVT
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$6.9B
CEOEric Venker
Employees315
HeadquartersDurham, NY, US
IPO date2019-06-21
Websiteimmunovant.com

What you can see for IMVT on Tickr

Live IMVT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMVT report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Immunovant, Inc.?

The ticker symbol for Immunovant, Inc. is IMVT, listed on the NASDAQ Global Select.

What is IMVT?

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a…

HomeExploreMarketLists
All pages